key: cord-0853551-pk1nbw4d authors: Kavadichanda, Chengappa; Shobha, Vineeta; Ghosh, Parasar; Wakhlu, Anupam; Bairwa, Devender; Mohanan, Manju; Janardana, Ramya; Sircar, Geetabali; Sahoo, Rasmi Ranjan; Joseph, Sneha; Negi, Vir Singh; Khanna, Dinesh; Shenoy, Padmanabha title: Clinical and psycho-socio-economic impact of COVID-19 pandemic on patients of the Indian Progressive Systemic Sclerosis Registry (IPSSR) date: 2021-04-23 journal: Rheumatol Adv Pract DOI: 10.1093/rap/rkab027 sha: 1e9c26d6fa5b74bf952af67cbfbbdc5378090101 doc_id: 853551 cord_uid: pk1nbw4d OBJECTIVES: To determine the impact of COVID-19 pandemic on access to healthcare among the patients with Scleroderma. To analyse the economic and psychosocial impact and the infection prevention measures taken by them during the pandemic. METHODS: A 25 item questionnaire designed to assess the components of the objectives was tele-administered between October 2020 and January 2021 to the patients enrolled in the Indian Progressive Systemic Sclerosis Registry registry. RESULTS: Out of the 428 patients in the registry, 336 took part in the study. Scheduled outpatient visit was missed by 310 (92.3%) patients and 75 (22.3%) skipped prescription drugs. During the pandemic, 75 (22.3%) had a family member lose jobs. Financial difficulties were reported by 155 (46.1%) with 116 (34.5%) patients having to spend an additional of INR 4000 (2000 to 10000) [USD 54.9 (27.0– 137.4)] to continue treatment. Though 35 patients (10.4%) had at least one symptom suggestive of COVID-19, confirmed infection was only in 4. None of them needed hospitalisation or had adverse outcomes. Worsening of Scleroderma was seen in 133 (39.6%) individuals with 15(4.5%) requiring hospitalisation. Most (96%) of the patients were aware about infection prevention measures and 91(27.1%) had taken unproven prophylactic medications. CONCLUSION: Individuals with Scleroderma in India have been affected during the pandemic due to closure of hospital services, lack of transport, loss of job and the additional financial burden. Healthcare providers should continue to educate patients to stay on their medications and encourage them to get vaccinated for COVID-19. The ongoing COVID-19 pandemic has brought to scrutiny the strengths and weaknesses of healthcare systems across the globe(1) (2) . The common theme emerging out of the scrutiny is that most systems across the world are not capable of identifying and addressing the needs of susceptible groups of individuals who need protection and specialised care during times of crisis.The susceptible groups like the elderly and those with chronic, diseases like psychiatric illness(3), malignancies(4)and autoimmune inflammatory rheumatic diseases (AIRD) (5, 6) have been badly affected during this pandemic. Given the abrupt changes caused by the pandemic and the mitigation measures imposed by the government, individuals who have a poor physical and functional status are likely to be affected the most. Among AIRDs, scleroderma or systemic sclerosis ( SSc) has a very high rate of mortality and morbidity (7, 8) with patients having poor physical and functional status. Individuals with AIRD including those with SSc require regular and periodic clinical assessment by rheumatologists and laboratory check-ups for the early detection of diseases worsening or other complications.SSc is characterised by skin thickening, vasculopathy and damage of digits and internal organs especially lungs, heart and gastrointestinal tract, leading to severe physical and psychological impairment (9) .With India announcing a strict nationwide lockdown from 23 rd March 2020 to 31 st May 2020 to contain the spread of COVID-19, followed by a gradual opening up of services from 1 st June 2020 onwards(10), most of the patients with chronic diseases were deprived of access to routine health care. In order to overcome the challenges in health care delivery during the pandemic, governments and health care providers have devised and rapidly implemented several simple and sustainable strategies (11) . Introduction of telemedicine and online consultations is one such strategy that has helped many chronically ill patients includingthose with SSc. Tele-rheumatology has not only helped patients seek timely healthcare but also has enabled clinicians effectively manage patient cohorts and continue research in a modified manner(12). The data generated by the tele-rheumatology consults and questionnaire based surveys will be handy in preparing for further catastrophes and addressing myths and beliefs among patients and their care providers. In this context there are limited studies done to understand the accessibility and availability of drugs used in rheumatology practice and health care services during the nation-wide lockdown. Also, there have been limited attempts to understand the challenges faced,health beliefs and practices of patients with SSc. Thus, this study aimed to determine the healthcare impact of COVID-19 pandemic by tele-consultationand the issues faced in continuing medications among the patients enrolled in theIndianProgressive Systemic Sclerosis Registry (IPSSR). We also analysed the psychosocial impact of COVID-19 pandemic on scleroderma patients and sought to understand the measures taken by patients with SSc to protect themselves from the SARS CoV 2 infection during the peak of the pandemic in India. and are followed up at 3 monthly intervals across all the centres. Institute ethics approval was obtained by all the participating centres. The present telemedicine-based study was designed to establish contact with the patients enrolled in the registry during the time of COVID-19. A questionnaire with 25 items was developed in English language by 2 experienced rheumatologists (Supplementary Data S1, available at Rheumatology Advances in Practice online). These questions were then discussed with the investigators from all the participating centres and finalised. The questions covered issues on healthcare delivery, medical complications during the lockdown, COVID related symptoms if any, preventive measures practiced by the patients and psychosocial issues. The questionnaire was then administered in the vernacular languages to research team by the rheumatologists to test for interlanguage reliability with the answers obtained (14) . After ascertaining the reliability of the questions, all the enrolled patients were contacted between October 2020 and January 2021on their registered mobile/telephone numbers and email ids. Those patients who consented to participate in the study were administered the questionnaire by a trained speciality nurse over telephone, WhatsApp, email or a video consult which was supervised by a rheumatologist. Verbal consent was obtained from the patients prior to administration of the questionnaire and waiver of written consent was obtained as this was a telemedicine-based study. The medical officer explained the questions along with all the options to the patient in English or their vernacular language (Malayalam, Tamil, Hindi, Bengali, Kannada or Telugu) and the feedback was documented manually on printed forms. The patient global assessment was done using the likert scale from 0 to 10 where zero meant feeling worst and 10 meant very good. The participants were not offered any kind of incentive for participating in the study. Once the questionnaire was filled, completeness check and multiple entries check was done by manually screening the entries by the study nurse. This was followed by telephonically assessing the scleroderma health associated questionnaire (SHAQ) and hospital anxiety depression scale (HADS). A HADS score of above 7 was considered abnormal for depression and anxiety separately (15) . The patients were also allowed to revise their previous responses if required during this call (16) . The data was then manually entered into an excel sheet and only completely filled questionnaires were analysed. The data was analysed using IBM SPSS Statistics 19 software. Continuous variables were represented as mean (S.D.) or median andinterquartile range (IQR) or range, as appropriate. The Kolmogorov-Smirnov test was used to check the normality of the quantitative data. Categorical variables like gender, disease status, presence of comorbidities, compliance, availability of drugs, COVID-19related symptoms and knowledge ofprecautions, a questionnaire assessing physical and mental health were described as frequencies and proportions. Variables determining abrupt stoppage of prescription drugs, flare of SSc symptoms and abnormal HADS score were compared using v2 or Mann-Whitney U test. A P-value of <0.05 was considered assignificant. The speciality nurse from each study centre attempted to contact 428 patients. Out of the 428 calls vitamin C (n=39) (11.6%) and Vitamin D (n=09) (2.7%). While the patients with SSc followed these preventive measures, 146 patients (43.5%) were apprehensive that their pre-existing diseases may flare up and 140 patients (41.7%) felt that they had a higher risk of getting the infection. We analysed the characteristics of the patients who had worsening of SSc symptoms during the lockdown (Table 4 ). One hundred and thirty-three patients experienced worsening of their scleroderma symptoms during the pandemic and the details of the symptoms are presented in table 2. Out of them 15 patients needed hospitalisation. Patients who had discontinued medications and those under psychological stress due to job loss or had a higher association with worsening of SSc related symptoms(p<0.01). One hundred and fourteen patients had abnormal scores (>7) for depression and 149 for anxiety. Further upon analysing the patients who had an abnormal (>7) depression and anxiety score on HADS we found that people who had a job loss or had financial difficulty and those who had worsening SSc symptoms were more likely to have abnormal HADS scores (p<0.01) ( Table 5 ). The present study analyzes the impact of COVID-19 pandemic on individuals with SSc who are enrolled in a nationwide multicentre registry. It is well established that telemedicine is a widely accepted modality of obtaining healthcare among patients with AIRDs both in India(17) and other parts of the world (18, 19) .It is interesting to note that even during the peak of COVID19 transmission The current telemedicine-based study shows that the pandemic and the associated containment measures imposed substantial logistic and financial burden on the patients and their families. In the cohort we observed that 22% of the patients, had at least 1 member in the family lost their job. Close to 50% of the families of patients faced financial difficulties. The result of these disruptions seems to be direct with over 90% of the patients with SSc missing their scheduled OPD visit and over 20% having to discontinue their drugs. This was similar to the reports from other parts of the world where over 2/3 rd of the patients reported disruption of scleroderma treatment services. The reason for discontinuing the drugs was mainly financial challenges faced by the families and unavailability of drugs, which was also reported by the survey conducted by EURORDIS-Rare Diseases Europe (22) . Besides drugs, patients with SSc often have periodic assessments like pulmonary function tests and echocardiograms involving doctors from other specialities which have all been discontinued during the pandemic (23) . Majority of the SSc patients switched to primary health care centres and online pharmacy to procure drugs, as they could not attend the tertiary care hospitals during the pandemic. These are encouraging trends which shows that patients are resourceful and motivated which will go a long way in future preparedness. Another important finding of our study is that psychological stressors like job loss along with obvious reasons like discontinuation of medication was associated with worsening of SSc symptoms.In a previous telemedicine based study we had reported that patients could greatly reduce their out of pocket expenditure if the facilities for drug distribution were optimised at the primary health care centre closest to their residence (24) . These results suggest that optimising online pharmacies and pharmacies at primary health care centres can help patients with chronic diseases both financially and psychologically. Earlier studies have shown that the patients with SSc greatly changed their lifestyle during the pandemic, adopting to more restrictive isolation measures, because of their awareness of frailty(25). A similar behaviour was self-reported in our cohort with the majority (>95%) of them abiding by the strict infection prevention practice like maintaining social distancing, wearing masks, isolating one self and avoiding stepping out of the houses. Most patients also practiced some unproven infection mitigation measures like washing the clothes of the person stepping out of the house in a separate batch (80%) and having bath after getting back home in case she/ he ventured out, besides taking prophylactic complementary alternative medicines and vitamins. It is yet to be understood if these behaviour changes were a result of fear of the pandemic or due to the sense of being frail among patients of AIRDs.Several symptoms like cough, dyspnoea and diarrhoea which qualify for screening of COVID-19 infection were seen among patients with SSc but were not due to COVID-19. Similar incidence of probable and definite symptoms of COVID-19 infection among patients with SSc has also been reported from Italy (26) . Most of these symptoms are not specific for COVID and can also be seen with worsening diseases activity in SSc. It is important for the physicians treating COVID-19 to judiciously screen these patients for infections and fast-track the referral of these patients to a specialist if negative for infection. This will help the rheumatologist to optimise treatment for SSc, thus preventing long term complications. Over 30% of patients had abnormal scores for depression and anxiety. The prevalence of abnormal scores in patients with rheumatic diseases are similar to those reported from other countries (27) . Our study, shows association between worsening of SSc symptoms not only with drug discontinuation but also with psychological stressors like job loss and family members being diagnosed with COVID-19. This highlights the need to have a holistic approach and to include management of mental health problems among these patients. These psycho-socioeconomic and clinical factors seem to be reflected in the higher association with depression and anxiety scores among our patients. Though we do not have a pre COVID value of HADS, the factors associated with higher scores shows the high indirect morbidity in SSc during the pandemic. Similar results were also shown by a global e-survey of individuals with SSc(28) and a web based survey from India which showed higher levels of anxiety among patients with AIRDs (29) . Our study has a few limitations in that the pre COVID-19 health and psychological status of these patients were not included in this study. Secondly, we could not reach nearly one fourth of the patients due to various reasons, which is a drawback of conducting survey-based research. Besides these, being a questionnaire-based survey, the study may have response bias, where the individual may have over or under scored the questions. But there are a few strengths, that could negate these short comings. The study involved a large cohort of SSc from different strata of society and different geographical locations across India also reflected by similarity in demographic characteristics previously reported by a different group (30) . Moreover, very few other studies have documented the experience of patients during and after the peak of COVID-19 infection. Our observations show that the individuals with SSc seem to have been affected during the pandemic on three fronts. First, the constant fear of contracting COVID-19 resulting in a poor outcome as a consequence of the pre-existing condition or medications. Second, the difficulty in accessing health care due to the abrupt change in the access, quality, and the way routine health care is delivered during the pandemic. Third, the economic crisis and loss of employment due to the pandemic. These findings highlights the fact that healthcare providers should continue to educate patients to stay on their medications and encourage them to get vaccinated for Covid-19 infection. A close and complementary working between governmental agencies and private players to ensure continuity of care, availability of drugs and optimisation of teleconsultation for specialist opinion will help us mitigate these challenges to a large extent. Besides addressing these aspects, mechanisms to address the mental health issues needs to be devised urgently to help patients with SSc cope with the circumstances. Such working models can be extrapolated to the care of most of the chronic diseases and can go a long way in strengthening our healthcare system. Covid-19 and the Need for Health Care Reform Learning from Adversity: Lessons from the COVID-19 Crisis COVID-19 Pandemic: Impact on psychiatric care in the United States Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands COVID-19 and Its Potential Effect on Patients With Rheumatic Diseases in Latin America The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum Circulars for Covid-19 | Ministry of Home Affairs | GoI Telemedicine Practice Guidelines Enabling Registered Medical Practitioners to Provide Healthcare Using Telemedicine Impact of the COVID-19 pandemic on patients with systemic lupus erythematosus: Observations from an Indian inception cohort Reporting Survey Based Studies -a Primer for Authors The hospital anxiety and depression scale Switching to teleconsultation for rheumatology in the wake of the COVID-19 pandemic: feasibility and patient response in India The attitude of Polish rheumatology patients towards telemedicine in the age of the COVID-19 pandemic Response to: 'Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort' by Costa et al Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Impact of Covid-19 on clinical care and lived experience of systemic sclerosis: An international survey from EURORDIS-Rare Diseases Europe Survey of current practice of scleroderma management in India Tele-rheumatology for overcoming socioeconomic barriers to healthcare in resource constrained settings: lessons from COVID-19 pandemic COVID-19 and systemic sclerosis: analysis of lifestyle changes during the SARS-CoV-2 pandemic in an Italian single-center cohort COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey Patient Perspectives on the Effect of the SARS-CoV-2 Pandemic on Patients With Systemic Sclerosis: An International Patient Survey Psychological Impact of Coronavirus Disease 2019 Pandemic on Patients with Rheumatological Disorders: A Web-based Cross-Sectional Multicentric Survey Clinical and Autoimmune Profile of Scleroderma Patients from Western India